Abstract:Cancer targeting gene-viro-therapy (CTGVT) approach has become a hotspot and a trend in the field of cancer biotherapy and oncolytic adenovirus is an ideal vector to carry the targeting genes. In this study, we used human telomerase reverse transcriptase (hTERT) promoter to control the adenovirus early region 1a (E1A) and the human α-fetoprotein (AFP) promoter integrated with hypoxia response element (HRE) to control the adenovirus early region 1b (E1B). Then the novel double-regulated adenovirus Ad-hTERT-HREAF (named SG505) was engineered. The short-hairpin RNA against focal adhesion kinase (FAK) was inserted into SG505 and thus forming Ad-hTERT-HREAF-shRNA (called SG505‑siFAK). Then various oncolytic adenoviruses were examined to verify whether they could suppress liver cancer cells selectively and efficiently both in vitro and in vivo. Both replicative and replication-defective adenoviruses carrying FAK-shRNA significantly inhibited the expression of FAK in Hep3B and SMMC-7721 cell lines and efficiently suppressed the growth of liver cancer cell lines with minor effect to normal cells. Furthermore, the recombined oncolytic adenoviruses, SG505-siFAK, SG505-EGFP and SG505 were able to selectively propagate in AFP-positive liver cancer cells in vitro and the SG505-siFAK efficiently suppressed the expression of FAK. SG505-siFAK showed the most potent tumor inhibition capability among the three recombined adenovirus with IC50 levels of 0.092±0.009 and 0.424±0.414 pfu/cell in the Hep3B and HepG2 cell line, respectively. Animal experiment further confirmed that SG505-siFAK achieved the most significant tumor inhibition of Hep3B liver cancer xenografted growth by intratumoral injection comparing to the intravenous injection among the three recombined viruses. Immunohistochemical results indicated that FAK expression was downregulated significantly in the tumors treated with SG505-siFAK. The dual-regulated oncolytic adenovirus SG505-siFAK was proven to inhibit the growth of liver cancer cells selectively and efficiently, therefore SG505-siFAK could be a potential agent for future clinical trials of hepatocellular carcinoma.

[Tumor-Targeting Expression of a New Tumor Suppressor Gene HCCS1 and Its Tumor-Selective Inhibitory Effects on Hepatocellular Carcinoma].

Adenovirus-mediated HCCS1 overexpression elicits a potent antitumor efficacy on human colorectal cancer and hepatoma cells both in vitro and in vivo

Bc047440 Antisense Eukaryotic Expression Vectors Inhibited Hepg(2) Cell Proliferation and Suppressed Xenograft Tumorigenicity

Potent Anti-Hepatoma Efficacy of HCCS1 Via Dual Tumor-Targeting Gene-Virotherapy Strategy.

Adenovirus-mediated Tissue-Specific Cytosine Deaminase Gene Therapy for Human Hepatocellular Carcinoma with Different AFP Expression Levels.

Cell-Specific Expression of Artificial Micrornas Targeting Essential Genes Exhibit Potent Antitumor Effect on Hepatocellular Carcinoma Cells

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Increased Safety With Preserved Antitumoral Efficacy On Hepatocellular Carcinoma With Dual-Regulated Oncolytic Adenovirus

Conditionally Replicative Adenovirus Vector Carrying Trail Gene For Enhanced Oncolysis Of Human Hepatocellular Carcinoma

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma

Antiangiogenesis Gene Armed Tumor‐targeting Adenovirus Yields Multiple Antitumor Activities in Human HCC Xenografts in Nude Mice

[Recombinant Adenovirus Vectors Carrying Antisense Matrix Metalloproteinase-2 Inhibits Hepatocellular Carcinoma Growth in Vivo].

Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.

Gene Therapy Targeting Hepatocellular Carcinoma by A Dual-Regulated Oncolytic Adenovirus Harboring the Focal Adhesion Kinase Shrna

Construction of a regulable gene therapy vector targeting for hepatocellular carcinoma

[Recombinant Adenovirus Vectors Carrying Antisense MMP2 Inhibit Invasion of HCC Cells in Vitro].

An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma.

Construction of a New Type Replication-Selective Adenovirus CNHK600-p53 and Its Inhibitory Effect on Hepatocellular Carcinoma Cells in Vitro

E1a-Engineered Human Umbilical Cord Mesenchymal Stem Cells As Carriers and Amplifiers for Adenovirus Suppress Hepatocarcinoma in Mice

Construction of Tumor-specific Oncolytic Adenovirus Vector and its Primary Study on Selective Expression in Tumor Cells

Targeting of Hepatoma Cell and Suppression of Tumor Growth by A Novel 12mer Peptide Fused to Superantigen Tsst-1